Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05747924 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
A Phase 1 study of FSHD and Fascioscapulohumeral Muscular Dystrophy, sponsored by Avidity Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 17
- Study locations
NCT05747924 is a Phase 1 study of FSHD and Fascioscapulohumeral Muscular Dystrophy that is active but no longer recruiting, run by Avidity Biosciences. The registered enrollment target is 90 participants, below the 1,883-participant average among 3 other FSHD trials with a reported enrollment target (95% lower). The trial reports 17 study locations across 14 states.
The verdict
NCT05747924, a Phase 1 study of FSHD and Fascioscapulohumeral Muscular Dystrophy, is active but no longer recruiting, sponsored by Avidity Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 17
- Study locations
Study Summary
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AOC 1020
Study Locations (17)
California
- University of California Los Angeles - Los Angeles
- Stanford University - Palo Alto
- University of California San Diego - San Diego
Other
- University College London - London
- University of Sheffield - Sheffield
Colorado
- University of Colorado - Denver
Florida
- University of Florida - Gainesville
Georgia
- Rare Disease Research - Atlanta
Kansas
- Kansas University Medical Center - Kansas City
New York
- University of Rochester Medical Center - Rochester
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05747924
The ClinicalTrials.gov registry entry for NCT05747924 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,883-participant average among 3 other FSHD trials with a reported enrollment target (95% lower). The listed sponsor is Avidity Biosciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with FSHD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05747924 reports 17 study locations spanning 14 distinct geographic areas - top geographies include California, Other, Colorado.
Frequently Asked Questions
What is clinical trial NCT05747924 about?
NCT05747924 is a clinical study titled "Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)". A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
What is the current status of trial NCT05747924?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2023-04-04. Estimated completion is 2027-04.
What conditions does trial NCT05747924 study?
This clinical trial studies the following conditions: FSHD, Fascioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Fascioscapulohumeral Muscular Dystrophy Type 1.
What interventions are being tested in trial NCT05747924?
The interventions under investigation include: Placebo (DRUG), AOC 1020 (DRUG).
Who is sponsoring clinical trial NCT05747924?
This trial is sponsored by Avidity Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05747924 being conducted?
This trial has 17 study locations across California, Colorado, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for FSHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.